Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Wuhan Hiteck Biological Pharma Co Ltd
Total Liabilities
Wuhan Hiteck Biological Pharma Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
|
Total Liabilities
¥403.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities
¥26.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Liabilities
¥18B
|
CAGR 3-Years
38%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Liabilities
¥3.6B
|
CAGR 3-Years
52%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Liabilities
¥7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Liabilities
¥1.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Wuhan Hiteck Biological Pharma Co Ltd
Glance View
Wuhan Hiteck Biological Pharma Co., Ltd. engages in the research, development, production, and sale of chemicals including biological products and thrombin. The company is headquartered in Wuhan, Hubei and currently employs 1,143 full-time employees. The company went IPO on 2017-08-08. The firm operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segment’s businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
See Also
What is Wuhan Hiteck Biological Pharma Co Ltd's Total Liabilities?
Total Liabilities
403.3m
CNY
Based on the financial report for Sep 30, 2025, Wuhan Hiteck Biological Pharma Co Ltd's Total Liabilities amounts to 403.3m CNY.
What is Wuhan Hiteck Biological Pharma Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
0%
Over the last year, the Total Liabilities growth was -20%. The average annual Total Liabilities growth rates for Wuhan Hiteck Biological Pharma Co Ltd have been 7% over the past three years .
